Urinary kallikrein: A marker of blood pressure sensitivity to salt  by Madeddu, Paolo et al.
Kidney International, VoL 49 (1996), pp. 1422—1427
Urinary kallikrein: A marker of blood pressure sensitivity to salt
PAOLO MADEDDU, MARIA VrrroRIA VARONI, MARIA PIE1t DEMONTIS, PAOLO PINNA-PARPAGLIA,
Nicoi GLoRIoso, and VirroRlo ANANIA
Clinica Medica and Farinacologia, University of Sassari, Sassari, Italy
Urinary kallikrein: A marker of blood pressure sensitivity to salt. We
evaluated if a rat strain inbred for low urinary kallikrein excretion differs
from normal-kallikrein Wistar rats regarding blood pressure levels in basal
conditions and during alterations in sodium balance. Blood pressure was
measured in unanesthetized rats on normal sodium intake. Then, blood
pressure sensitivity to salt was evaluated over a period of 20 days of high
sodium diet (0.84 mmol per g chow). Low-kallikrein rats showed greater
systolic blood pressure levels (125 3 vs. 114 2 mm Hg in controls,
P < 0.01) at nine weeks of age. Systolic blood pressure was increased after
sodium loading in the low-kallikrein group and remained unchanged in
controls (150 6 vs. 112 2mm Hg, P < 0.01). This effect was associated
with a reduced cumulative urinary excretion of sodium in the low-
kallikrein rats. No group difference was found in the clearance of
endogenous creatinine in basal conditions. Urinary creatinine excretion
decreased during sodium loading, particularly in the low-kallikrein group.
The group-difference in urinary kallikrein excretion found in basal condi-
tions (6.85 0.31 vs. 20.74 1.71 nkat/24 hr in controls, P < 0.01) was
enhanced by high salt diet (2.96 0.67 vs. 22.07 2.47 nkat/24 hr in
controls, P < 0.01). In addition, renal kallikrein activity and content were
reduced in low-kallikrein rats. The latter group showed a greater ratio of
heart weight to body wt both in basal conditions and after sodium loading.
The ratio of kidney weight to body wt was reduced after sodium loading.
These results indicate that a genetically-determined defect in urinary
kallikrein excretion is associated with a greater blood pressure sensitivity
to salt, possibly due to altered renal sodium handling.
The renal kallikrein-kinin system may be implicated in the
pathogenesis of arterial hypertension. Decreased urinary kal-
likrein excretion is found in essential hypertensive patients and in
their normotensive offspring [1], as well as in different rat models
of genetic hypertension. Cosegregation of a sequence variation of
the kallikrein gene with high blood pressure phenotype in inbred
strains derived from the spontaneously hypertensive rat (SHR)
and the normotensive Brown Norway rat confirms that this gene
may have the capacity to affect blood pressure [2. Kinins, which
are derived from the enzymatic action of kallikrein on kininogen,
are able to induce vasodilation, diuresis and natriuresis. It is
therefore conceivable that sodium retention and body fluid ex-
pansion contribute in the pathogenesis of hypertension in subjects
with depressed activity of the renal kallikrein-kinin system, and in
fact the latter abnormality has been used as a marker of salt-
sensitivity in normotensive subjects as well as in essential hyper-
tensive patients [3, 4]. However, in spite of the high genetic
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control of renal kallikrein expression, common environment plays
a significant role in its overall variance [5, 6]. Thus, the extent of
genetic determination in the association between salt-sensitivity
and low kallikrein phenotype remains unknown. Recently, a strain
was developed in our laboratory by breeding rats from a Wistar
stock according to their urinary kallikrein phenotype. Selection of
a genetically-determined low kallikrein phenotype would help
clarify whether the latter is associated with higher basal blood
pressure levels and with an enhanced blood pressure sensitivity to
salt. The aim of the present study was twofold: (1) to evaluate if
the basal blood pressure of the low-kallikrein strain differs from
that of normal-kallikrein Wistar rats, and (2) to determine
possible differences in the blood pressure sensitivity to a dietary
salt excess.
Methods
Experiments were performed in a rat strain originated from an
outbred Wistar colony (Morini, Como, Italy). From this popula-
tion, lines were established by two-way selection for high and low
urinary kallikrein excretion. Unfortunately, the high kallikrein
line was affected by a high degree of infertility that led to
extinction of the strain. No breeding problems were encountered
with the low-selection line, which was propagated by sister-
brother mating exclusively. This strain showed an initial decline in
kallikrein excretion until the fifth generation (F5). Then, urinary
kallikrein remained constant until F20, with a clear-cut difference
between genders (lower kallikrein levels in males). For the
present study, normal Wistar rats (from Morini) were mated in
our laboratory and their offspring were used as controls.
Rats were housed at a constant room temperature (24 1°C)
and humidity (60 3%) with a 12-hour light/dark cycle. They had
free access to rat chow (sodium, 0.12 mmol/g, Mucedola, Milan,
Italy) and tap water. All procedures complied with the standards
for the care and use of animals as stated in Guide for the Care and
Use of Laboratory Animals (Institute of Laboratory Animal Re-
sources, National Academy of Science, Bethesda, MD, USA).
Experiment 1. Kallikrein activity and immunoreactive kallikrein
levels in urine and renal homogenates in basal conditions
To determine the urinary concentration of kallikrein, creatinine
and of N-acetyl-f3-D-glucosaminidase (UNAG), 24-hour urine col-
lections were obtained at eight and nine weeks of age from
controls and low-kallikrein rats (N = 11 males, each group),
maintained in individual metabolic cages. During the collection
periods, rats had free access to water but were deprived of food.
At nine weeks, they were anesthetized with ether and blood was
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taken by direct puncture of the heart to measure plasma creati-
nine. After transcardial perfusion with 20 mL saline, the heart and
both kidneys were removed, cleaned, washed in saline, blotted
and weighed. Kidneys were then minced and homogenized in 0.1
mol/liter Tris-HC1 buffer (pH 8.2) with a mechanical homogenizer
(Ultra Turrax, Janke & Kunkel KG, Staufen, Germany). Since,
much of renal kallikrein is bound to plasma membrane and
endoplasmatic reticulum, some kidneys (N =4, each group) were
homogenized in 10 ml 0.5% sodium deoxycholic acid (pH 8.5).
This mixture was incubated for 30 minutes and then sonicated
with a microultrasonic cell disrupter (Sonorex; Bandelin Elec-
tronic, Berlin, Germany). Homogenates were centrifuged at
17,000 g for 40 minutes. All above procedures were carried out at
4°C. Supernatants were then stored at —40°C until assay.
Experiment 2: Effect of high sodium intake on the systolic blood
pressure of low-kallikrein rats
Rats were fed a diet with normal sodium content (0.12 mmol
per g chow) until the ninth week of age. At this stage, both the
control and the low-kallikrein group (N = 8 males each) were
assigned to a high (0.84 mmol per g chow) sodium diet for the
following 20 days. Concentration of the other nutrients in the
chow was not modified. At the end of this period, rats returned to
the initial diet (sodium, 0.12 mmol per g chow) for one additional
week. Twenty-four-hour urine collections were obtained before
and over the first five days of the high sodium diet. During the
collection periods, rats were maintained in individual metabolic
cages, which allowed for a high degree of accuracy in the
measurement of food and water intake by the inclusion of spill
catches. The chow was ground and blended before use. Systolic
blood pressure (SBP), heart rate (HR), and body wt (body wt)
were measured weekly starting from the seventh until the ninth
week of age and then every five days. SBP and HR were measured
by the tail-cuff plethysmography method (Recorder 8002, Ugo
Basile, Biological Research Apparatus, Comerio, Italy) in unanes-
thetized rats pre-warmed for 10 minutes at 37°C in a thermostat-
ically controlled heating cabinet. Each pressure value was ob-
tained by averaging eight to ten individual readings. At the end of
the experiments, rats were killed with an excess of ether anesthe-
sia, and the heart and both kidneys were removed, cleaned,
washed in saline, blotted and weighed.
Analytical procedures
Urinary volume (UV) was determined gravimetrically. Sodium
(UNa) and potassium (UK) concentration in urine was determined
by flame photometry and urinary daily excretion was calculated
according to the formulas: UNaV = UNa UV and UKV = UK
UV, respectively. Creatinine concentration in plasma (Plr) and
urine (Ur) was measured by an automatic analyzer (Hitachi 704).
The clearance of endogenous creatinine was calculated according
to the formula: Clearancecr = UV Uç/l44O Plr and expressed
in tl/min per 100 mg kidney weight. Kallikrein activity in urine
and homogenates was measured by an end point amidolytic
method [7] at 37°C in 0.1 mol/liter Tris-HC1 buffer (pH 8.2)
containing soybean trypsin inhibitor (SBTI, 300 g/m1 Sigma
Chemical Company, St. Louis, MO, USA). The latter substance
was included in the incubation buffer to inhibit plasma kallikrein
and trypsin-like enzymes. The reaction was started by adding
substrate (D-Val-Leu-Arg-p-nitroanilide, S2266, Kabi Diagnos-
tica, Stockholm, Sweden) to the final concentration of 1.5 mmol/
liter. The increase in optical density (O.D.), that is proportional to
the rate of p-nitroaniline formation, was measured at 405 nm
every hour (Perkin-Elmer, Oak Brook, IL, USA). The above
procedure ensured that the rate of p-nitroaniline released during
the incubation was linear (that is, less than 5% of the substrate
was consumed). The reaction was stopped by adding 100 jl of
50% (vol/vol) acetic acid. In contrast with esterolytic assays, the
method based on S-2266 substrate has been shown to be specific
for glandular kallikrein {8]. As stated above, SBTI was added to
the incubation buffer to enhance specificity. In addition, each
experimental sample had two controls which consisted of: (1) the
same sample incubated with substrate in the presence of 50 U/ml
aprotinin (Sigma Chemical Company), a glandular kallikrein
inhibitor; and (2) the same sample incubated with substrate in the
presence of 30 nmol/liter polyclonal antibodies against human
glandular kallikrein. Kallikrein affinity-purified sheep anti-rat
glandular kallikrein antibodies [9] were kindly provided by Dr.
Julie Chao, University of South Carolina. The ability of antibodies
to inhibit the activity of rat glandular kallikrein was preliminary
tested on the synthetic substrate S-2266. Since the O.D. of the
controls containing aprotinin did not differ from that of the
samples incubated with kallikrein antibodies, for final calculations
the former was subtracted from O.D. of the corresponding
experimental samples. Therefore, kallikrein activity was measured
as amidolytic activity inhibited by aprotinin and kallikrein anti-
bodies, but resistant to SBTI. It was expressed in katals (kat) per
mL urine or 100 mg kidney weight (1 kat represents the enzyme
activity able to cleave 1 mol p-nitroaniline per second).
Kallikrein levels in urine and homogenates were also deter-
mined by a highly sensitive and specific radioimmunoassay for rat
glandular kallikrein [10] and expressed as g per ml or ng per 100
mg kidney weight, respectively. We found a significant correlation
between immunoreactive kallikrein levels and amidolytic activity
values in rat urine (y = 3.08x + 0.29, where y and x represent
immunoreactive kallikrein and kallikrein activity, respectively;
N = 24, r = 0.977, P < 0.001). To calculate urinary excretion,
kallikrein activity or immunoreactive kallikrein levels were multi-
plied by UV.
Urinary concentration of NAG was measured by a colorimetric
assay (Shionogi & Co. Ltd., Osaka, Japan) immediately after
collecting the sample and expressed in U/ml (1 U represents the
enzyme activity that releases 1 mmol 3-cresolsulfonphthalein per
mm from the substrate 3-cresolsulfonphthaleinyl-N-acetyl-p-D-
glucosaminidase). Protein concentration in renal homogenates
was determined by the method of Lowry et al [11].
Statistical analysis
All data are expressed as mean SEM. Multivariate repeated-
measures ANOVA was performed to test for interaction between
time and grouping factor. Univariate ANOVA then was used to
test for differences among groups and over time. Differences
within or between groups were determined using paired or
unpaired Student's t-test, respectively, with the Bonferroni multi-
ple-comparison adjustment. A probability (P) of 0.05 was used as
the criterion of significance. Mathematical and statistical analysis
were performed with a STATVIEW II package (Brain Power) on
an Apple Macintosh IICX computer.
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Results
Experiment 1. Kallikrein activily and immunoreactive kallikrein
levels in urine and renal homogenates in basal conditions
Urinary kallikrein excretion was lower in the experimental
group compared with the control group at eight weeks (amidolytic
method, 10.7 1.6 vs. 21.5 4.9 nkat/24 hr; RIA, 37.3 2.8 vs.
57.2 8.3 .tg/24 hr; P < 0.05 for both comparisons) as well as at
nine weeks of age (amidolytic method, 10.3 1.1 vs. 22.2 3.2
nkat/24 hr; RIA, 36.6 1.8 vs. 60.4 6.2 jt24 hr; P < 0.01 for
both comparisons). Immunoreactive kallikrein levels of renal
homogenates were reduced in low kallikrein rats after normaliza-
tion by kidney weight (71.1 4.1 vs. 92.4 3.0 ngIlOO mg kidney
wt in controls, P < 0.005) or protein content (12.0 3.5 vs. 15.6
0.9 ng/mg protein in controls, P = 0.05), while kallikrein activity
was similar in the two groups (16.6 1.4 vs. 16.4 1.6 pkat!100
mg kidney wt in controls, and 2.8 0.3 vs. 2.9 0.3 pkat/mg
protein, NS for both comparisons). However, a group-difference
in renal kallikrein activity was detected when homogenates were
incubated with sodium deoxycholic acid and sonicated (21.9 1.2
vs. 37.8 2.1 pkat/100 mg kidney wt in controls, 3.7 0.3 vs. 6.7
0.4 pkat/mg protein, P < 0.05 for both comparisons, N = 4 each
group).
The clearance of endogenous creatinine, an indirect measure of
glomerular filtration rate, was similar in the two groups (33.7
2.8 vs. 37.1 0.5 j.d/min per 100 mg kidney weight in controls,
NS), whereas the urinary excretion of NAG was significantly
increased in low-kallikrein rats [0.57 0.03 (range 0.37 to 0.75)
vs. 0.33 0.05 (range 0.21 to 0.36) U/24 hr in controls, P < 0.OOfl.
The ratio of heart weight to body wt was greater in low-
kallikrein rats (322 5 vs. 296 5 mg/100 g body wt in controls,
P < 0.01), whereas the ratio of kidney weight to body wt was
similar (358 4 vs. 331 6 mg/lOU g body wt in controls, NS).
Experiment 2: Effect of high sodium intake on the systolic blood
pressure of low-kallikrein rats
As indicated in Figure 1, the low-kallikrein group showed
greater SBP levels (125 3 vs. 114 2 mm Hg in controls, P <
0.01) at nine weeks of age. SBP increased similarly in the two
groups during the first 10 days of salt loading. It then returned to
basal levels in the control group, whereas a further increase was
observed in the low-kallikrein group (150 6 vs. 112 2 mm Hg
in controls at 20 days, P < 0.01). A difference in SBP was still
observed five days after the rats had returned to normal sodium
diet (129 3 vs. 111 2 mm Hg in controls, P < 0.01).
As shown in Figure 2, the urinary excretion of kallikrein
(expressed as amidolytic activity or immunoreactive enzyme) was
significantly decreased in the experimental group compared with
controls. The group-difference in amidolytic activity was enhanced
after three days of high salt diet, due to a significant decrease of
the enzyme activity in urine of low-kallikrein rats, while immuno-
reactive kallikrein levels were not altered by salt loading in either
group. As a consequence, the ratio of amidolytic activity to
immunoreactive kallikrein excretion was significantly reduced in
low-kallikrein rats and this difference became more evident after
high salt.
No group difference was detected in basal body wt (Fig. 1) and
daily intake of food and water (18.0 0.9 g and 31.4 2.3 ml vs.
17.6 0.5 g and 28.7 1.3 ml, respectively, in controls, NS). Body
weight gain of the low-kallikrein rats fed high sodium diet was
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Fig. 1. (A) Systolic blood pressure (SBP), heart rate (B; HR) and body wt(C; BW) values in low kallikrein rats (•) and controls (0). Rats were given
a normal sodium diet until nine weeks of age (time 0) and then were
assigned to a high sodium diet for 20 days. Then rats returned to the initial
diet for an additional seven days. Values are mean SCM. < 0.05
versus control group, +P < 0.01 versus basal (time 0).
greater than that of controls (Fig. 1), while no significant differ-
ence was observed regarding the cumulative intake of food and
water. As shown in Table 1, the two groups did not differ in basal
conditions as far as UV, UNaV, and UKV are concerned, whereas
urinary creatinine excretion was lower in low-kallikrein rats. UV
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Normosodic Hypersodic
diet diet
Fig. 2. Urinaty kallikrein excretion, expressed as amidolytic activity (A) and
immunoreactive kallikrein (B), and the ratio of amidolytic activity to
immunoreactve kallikrein (C) in rats inbred for a low urinaiy kallikrein
phenotype (LI) and nonnal Wistar rats (U), in nonnosodic conditions and
after three days of hypersodic diet. Values are mean SEM. *P < 0.01 versus
normal Wistar rats, +P < 0.01 versus normosodic conditions.
and UNaV increased in both groups during the first five days of
high sodium diet; however, the cumulative UNaV of the low-
kallikrein group was 23% less than that controls (28.9 2.7 vs.
37.7 5.2 mmol/100 g body wt, P < 0.01), while the cumulative
UV was similar (107 18 vs. 111 16 ml/100 g body wt, NS). As
a consequence, sodium balance (expressed as the difference
between dietary intake and urinary excretion) was positive in the
low-kallikrein group and negative in controls (3 vs. —5 mmol
Na/100 g body wt). Urinary creatinine excretion was decreased by
sodium loading in both groups, but this effect was more pro-
nounced in the low-kallikrein group (Table 1).
At the end of the experiments, the ratio of heart weight to body
wt was significantly greater in low-kallikrein rats (331 7 vs. 275
4 mgIlOO g body wt in controls, P < 0.01), whereas the ratio of
kidney weight to body wt was lower (329 5 vs. 370 8 mg/100
g body wt in controls, P < 0.01).
Discussion
Urinary kallikrein excretion has been reported to be decreased
in various models of genetic hypertension including the Okamoto-
Kyoto (SHR), New Zealand and Milan hypertensive strains and
Dhal salt-sensitive rats [12—14]. At variance with the models
reported above, our rat strain was derived by selective breeding
for low urinary kallikrein excretion and not on the basis of high
blood pressure levels. This is an important difference since the
low-kallikrein phenotype of genetic models of hypertension could
be secondary to the increase in blood pressure.
Rat urine contains kallikrein-like enzymes, such as esterase A,
able to cleave synthetic substrates used in the past for the
determination of kallikrein activity. The amidolytic method em-
ployed in the present study is much more specific compared with
esterolytic assays. Some modifications of the method of Amund-
sen et al [7], such as the inclusion of a blank containing antibodies
against glandular kallikrein, were introduced to enhance specific-
ity. This discounts the possibility that the decrease in enzymatic
activity found in our inbred strain is due to interference of
unrelated enzymes. Validation of the amidolytic method was
obtained by measuring kallikrein levels with a radioimmunoassay
specific for rat glandular kallikrein. Application of the two
methods allowed us to recognize that both kallikrein activity and
immunoreactive kallikrein levels are decreased in the urine of the
imbred strain at eight as well as nine weeks of age. Renal
kallikrein levels were also reduced, while kallikrein activity of
renal homogenates was found to be decreased only after solubi-
lization of membrane-bound enzyme by deoxycholic acid. Renal
kallikrein is a plasma membrane-bound enzyme, synthesized (as
active form and inactive precursor) in the tubular cells of the
distal nephron and then released into the urine as well as the
interstitial compartment of the kidney. Our results support the
hypothesis that both the synthesis and the release of kallikrein
could be altered in this strain. In addition, the reduction in urinary
kallikrein activity might be attributable to: (1) an excess of
inhibitors or (2) a defect in the activation process of the inactive
precursor. Relevant to the first possibility is the concept that the
activity and function of tissue kallikrein are regulated by endog-
enous kallikrein-binding proteins or kallikrein inhibitors. One
such kallikrein-binding protein, kallistatin, is present in rat kidney
and forms a covalent complex with tissue kallikrein thus inhibiting
its activity [15]. It would be of interest to determine if kallistatin
levels are increased in the kidney and urine of the strain imbred in
our laboratory. Kallikrein levels measured by radioimmunoassay
reflect total kallikrein, while the amidolytic assay allows to
determine the active component. Therefore, the result that the
ratio of amidolytic activity to immunoreactive kallikrein levels was
reduced in urine of low-kallikrein rats, particularly after sodium

































Parameter and Group 0 1 2 3
UV ml/100 g body wt
Control 7 1 23 2 19 4 24 4 23 3 22 3
Low-kallikrein 12 2 21 4 19 5 18 5 22 3 21 3
UNaV mmol/100 g body wt
Control 0.60 0.05 7.04 0.74a 7.07 0.70 8.86 0.99a 8.04 0.72a 6.72 0.98a
Low-kallikrein 0.47 0.07 4.72 0.74" 5.75 0.99a 6.18 0.9" 6.40 0.97"" 6.19 0.57"
UKV mmol/100 g body wt
Control 1.37 0.06 1.62 0.10 1.34 0.17 1.50 0.13 1.48 0.07 1.29 0.22
Low-kallikrein 1.11 0.11 1.34 0.17 1.46 0.15 1.39 0.16 1.32 0.14 1.25 0.11
Ur mgIIOO g body wt
Control 12.36 0.64 9.01 0.42" 9.96 0.82" 10.92 0.99 11.57 0.60 11.57 0.70
Low-kallikrein 8.74 0.30" 734 047ab 6.91 0.82"" 5.96 0.86"" 34 (J5b 553 0.64""
Values represent mean SEM. High sodium diet was started from day 1. Abbreviations are: UV, urinary volume; UNV, urinary sodium excretion;
UkV, urinary potassium excretion; Ur, urinary creatinine excretion.
P < 0.05 vs. day 0
bP < 0.05 vs controls
In normosodic conditions, the systolic blood pressure of low-
kallikrein rats exceeded by 11 mm Hg that of normal-kallikrein
rats, a difference that is consistent with the number observed in
rats with early post-natal and life-long blockade of bradykinin B2
receptors by the antagonist Hoe 140 [16] and with the predicted
contribution of kallikrein gene on overall blood pressure variabil-
ity [5]. We found that rats given Hoe 140 early after birth have
increased sodium concentration in serum and erythrocytes, thus
suggesting that sodium and fluid retention occurred as a conse-
quence of kinin blockade [161. It is relevant to this aspect that
dietary sodium restriction nullifies the effect of Hoe 140 on blood
pressure.
Environmental factors, such as excessive salt intake, can lead to
hypertension in humans and rats with genetical susceptibility [4,
12—14]. Among various putative genetic markers, low urinary
excretion of kallikrein reportedly predicts in which subjects an
increase in blood pressure occurs during high sodium diet [4]. In
the present study, application of dietary sodium loading induced a
significant increase in the blood pressure of normal Wistar rats as
well as in low-kallikrein rats. However, this effect was only
transient in controls, whereas it persisted and was more pro-
nounced in the strain inbred for the low-kallikrein phenotype. At
least 15 days of sodium loading were necessary to unmask blood
pressure sensitivity to salt in these rats. One week exposure to 2%
NaC1 diet was enough in kininogen-deficient rats [17], which are
able to generate very low levels of renal and urinary kinins. Given
the longer life span of humans, it is conceivable that difficulties in
the recognition of blood pressure sensitivity to salt is due insuffi-
cient duration of sodium loading in some experimental protocols.
The low-kallikrein rats showed a decreased urinary excretion of
sodium during salt loading. Similar results were reported in
kininogen-deficient Brown Norway Katholiek rats, that genetically
lack the ability to generate kinins [17]. The possibility that
alterations in renal filtration and/or tubular handling of sodium
are present in the low-kallikrein rats is supported by the following
changes induced by salt loading: (1) positive Na balance, (2)
reduced ratio of UNaV to UKV, (3) decreased excretion of
creatinine, and (4) increased body wt. It is noteworthy that the
latter effect was not associated to alterations in food intake,
though changes in energy requirements might have contributed in
determining the difference. Based on the above considerations, it
is conceivable that the observed increase in blood pressure is due
to sodium retention and total fluid volume expansion.
A trophic role of the kallikrein-kinin system in postnatal renal
development is suggested by the observation that early, life-long
blockade of bradykinin receptors suppresses renal growth and
reduces urinary creatinine excretion [16]. Consistent with this
possibility is our observation that the functional alterations re-
ported above in the low-kallikrein rats were associated with a
lower ratio of kidney weight to body wt. However, the latter result
was observed in rats whose kidneys were examined at the end of
high sodium diet and it ensued from an increase in body wt rather
than a decrease in kidney weight. By contrast, no group-difference
was observed in normosodic conditions. A systematic and sequen-
tial histological examination should be performed to ascertain if
the low-kallikrein phenotype is a marker of altered renal matura-
tion. No apparent alteration in the morphology and number of
glomeruli was detected at nine weeks of age (P. Madeddu,
unpublished observations). Creatinine clearance, an index of
glomerular filtration rate, was not altered in basal conditions in
low-kallikrein rats. By contrast, the urinary excretion of NAG, a
lysosomal enzyme located in the proximal renal tubules, was
enhanced. Urinary NAG is used as an early but unspecific marker
of renal damage for monitoring the secondary involvement of the
kidney in disorders such diabetes and arterial hypertension. The
enzyme activity is increased in these conditions because of de-
creased lysosome stability or a decreased rate of destruction of the
enzyme [18]. It is noteworthy that functional abnormalities of the
proximal renal tubules have been reported in the Milan hyperten-
sive strain, whose phenotype includes decreased levels of kal-
likrein in urine [15].
The greater ratio of heart weight to body wt observed in the
low-kallikrein subgroup may be attributable to the increased
hemodynamic load. However, the effect on heart weight appears
disproportionate to the modest concurrent increase in blood
pressure levels. Similar findings were reported in rats with early
blockade of bradykinin receptors [16].
The alterations found in the low-kallikrein rats may be the
consequence of genetic drifting and high incidence of recessive
traits occurring after continuous breeding of brother to sister. In
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Table 1. Effect of high sodium intake in rats with low kallikrein excretion and in controls
Day
4 5
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this regard, we emphasize that the aim of the present work was
not to determine if the low-kallikrein phenotype cosegregates with
higher blood pressure levels. This would require comparison with
the opposite high-kallikrein phenotype (that we failed to select,
due to a high degree of infertility) and hack-cross segregation
tests. Thus, the major conclusions that can be drawn from our
results is that inherited low urinary kallikrein phenotype does
favor an increased blood pressure sensitivity to salt, possibly
related to a renal alteration in sodium handling. While there is
much more that needs to be defined of this strain, it could prove
to be a useful animal model for the study of the renal kallkrein-
kinin system in salt-induced hypertension. In preliminary experi-
ments, we found that chronic intravenous infusion of rat kallikrein
prevents the blood pressure effects of sodium loading in the
low-kallikrein strain (P. Madeddu, unpublished observations).
Direct gene delivery of human tissue kallikrein causes a sustained
decrease in the blood pressure of SHRs, an effect that is associ-
ated to expression of the enzyme in the heart, kidney and lung
[19]. Testing kallikrein gene therapy in the low-kallikrein strain
would provide additional informations regarding the potential of
this new approach for treating salt-sensitive hypertension.
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